Charles River Expands Strategic Partnership With SAMDI Tech

Rhea-AI Summary

Charles River Laboratories (NYSE: CRL) has expanded its strategic partnership with SAMDI Tech, enhancing access to label-free high-throughput screening solutions in drug discovery. The collaboration enables Charles River to promote SAMDI's innovative technology, improving efficiency in measuring biochemical activities and binding events. This partnership builds on a successful agreement established in 2018, allowing Charles River clients to leverage SAMDI Tech's mass spectrometry platform for accelerated drug discovery. The initiative aims to provide clients with critical data faster, facilitating timely decision-making in the drug development process.

Positive

• Expansion of partnership with SAMDI Tech enhances drug discovery solutions.
• Charles River established as exclusive promoter of SAMDI's technology.
• Access to advanced label-free high-throughput screening solutions for clients.
• Potential to accelerate client drug discovery efforts through quality data.

Negative

• None.

Provides Greater Access to Label-Free High-Throughput Screening Solutions

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of their strategic partnership with Chicago, Illinois-based SAMDI Tech, Inc. Under the existing partnership, established in 2018, SAMDI Tech clients have access to Charles River’s collection of lead-like compounds for high-throughput screening (HTS). The expanded agreement establishes Charles River as the exclusive partner for the promotion of SAMDI Tech’s technology. This partnership will provide Charles River’s clients seamless access to the premiere, label-free high-throughput screening mass spectrometry (MS) platform in drug discovery.

The SAMDI technology combines self-assembled monolayers and MALDI MS, and addresses the throughput and sample preparation limitations of traditional MS screening methods.

The combination of Charles River’s end-to-end portfolio and industry-leading scientific bench with SAMDI Tech’s innovative technology and expertise in assay solutions has the potential to significantly accelerate and augment clients’ discovery efforts by measuring biochemical activities and binding events for virtually any target.

Approved Quotes

• “Our collaboration with SAMDI Tech is another step that we’re taking toward accelerating drug discovery and development. By generating quality data faster during hit identification, we can help our clients make critical go/no go decisions earlier in the process, to advance their programs.” –Wilbert Frieling, D.V.M., Corporate Senior Vice President, Global Discovery Services, Charles River
• “With over a decade of industry experience, SAMDI Tech has a well-respected track record of producing high quality data. We are excited to partner with them to bring this technology to our clients.” – Julie Frearson, Ph.D., Corporate Senior Vice President, Chief Scientific Officer, Charles River
• “We are excited to expand on our successful partnership with Charles River, whose clients will join our global client base to benefit from our label-free SAMDI technology, which continues to deliver cutting-edge solutions backed by high-quality, data-driven results.” –Emilio Cordova, PhD, MBA, Chief Executive Officer, SAMDI Tech

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005074/en/

Charles River Investor Contact:

Todd Spencer

Corporate Vice President, Investor Relations

+1- 781-222-6455

todd.spencer@crl.com

Charles River Media Contact:

Amy Cianciaruso

Corporate Vice President & Chief Communications Officer

+1-781-222-6168

amy.cianciaruso@crl.com

Source: Charles River Laboratories International, Inc.

FAQ

What is the recent partnership expansion involving Charles River Laboratories (CRL)?

Charles River Laboratories has expanded its partnership with SAMDI Tech, becoming the exclusive promoter of SAMDI's label-free high-throughput screening technology.

How does the SAMDI technology benefit Charles River's clients?

The SAMDI technology allows clients to access improved mass spectrometry solutions, enhancing their ability to measure biochemical activities and support drug discovery.

When was the original partnership between Charles River and SAMDI Tech established?

The original partnership between Charles River and SAMDI Tech was established in 2018.

What does the partnership between Charles River and SAMDI Tech aim to achieve?

The partnership aims to accelerate drug discovery and development by providing quality data faster during hit identification.

What is the significance of label-free high-throughput screening in drug discovery?

Label-free high-throughput screening improves efficiency in drug discovery by enabling rapid assessment of biochemical interactions without the need for labels.